RefloDx Wins Trans Atlantic Angel Grand Prize
July 10, 2025
RefloDx competed in a field of 81 companies worldwide and won the grand prize investment from the Trans Atlantic Angel Competition 7 on June 12. The diligence team scrutinized financial projections, commercialization, regulatory, and reimbursement strategies, as well as IP review, and conducted detailed interviews with advisors, clinicians, and the RefloDx management team, including Rudy Wilcox, CEO, and Greg Critchfield, MD, MS, executive chair.
BioUtah congratulates RefloDx, which also won their category in the 2025 Entrepreneur & Investor Summit pitch competition.
Recent News
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
- Sera Prognostics Appoints Scott Gleason CFO
- Merit Medical Announces Global Operations Leadership Transition
- Utah Life Sciences Innovation Caucus Breakfast
- Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
